Makito Mizunuma1, Yoshihito Yokoyama2, Masayuki Futagami1, Masahiko Aoki3, Yoshihiro Takai3, Hideki Mizunuma1. 1. Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan. 2. Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan. yokoyama@hirosaki-u.ac.jp. 3. Department of Radiology and Radiation Oncology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki, 036-8562, Japan.
Abstract
BACKGROUND: The aim of this study was to investigate the prognostic role of the pretreatment neutrophil-to-lymphocyte ratio (NLR) as a predictive marker prior to treatment of cervical cancer with radiation therapy (RT) alone or concurrent chemoradiation therapy (CCRT). METHODS: Fifty-six patients with squamous cell carcinoma (SCC) of the uterine cervix who underwent RT or CCRT from 2005-2013 at the Hirosaki University Hospital were retrospectively identified using electronic databases. Patients were divided into a high NLR group (≥2.5) and a low NLR group (<2.5). The efficacy of RT and CCRT in the two groups was compared. RESULT: Of the 56 patients, 35 were in the high NLR group and 21 were in the low NLR group. In comparison to a high NLR, a low NLR was significantly associated with a complete response (P < 0.001). When cancer was divided into stages I/II and III/IV, patients with a low NLR had a significantly better therapeutic outcome than those with a high NLR (P < 0.05). Multivariate analysis showed that only the NLR was a significant prognostic factor for progression-free survival (PFS) and overall survival (OS). Patients with a high NLR had significantly shorter PFS and OS than those with a low NLR. CONCLUSION: Results showed that a low NLR before treatment could predict a good response to RT or CCRT at all stages of uterine cervical cancer. The NLR may be a promising parameter on which to base the choice of a therapeutic strategy to treat SCC of the uterine cervix.
BACKGROUND: The aim of this study was to investigate the prognostic role of the pretreatment neutrophil-to-lymphocyte ratio (NLR) as a predictive marker prior to treatment of cervical cancer with radiation therapy (RT) alone or concurrent chemoradiation therapy (CCRT). METHODS: Fifty-six patients with squamous cell carcinoma (SCC) of the uterine cervix who underwent RT or CCRT from 2005-2013 at the Hirosaki University Hospital were retrospectively identified using electronic databases. Patients were divided into a high NLR group (≥2.5) and a low NLR group (<2.5). The efficacy of RT and CCRT in the two groups was compared. RESULT: Of the 56 patients, 35 were in the high NLR group and 21 were in the low NLR group. In comparison to a high NLR, a low NLR was significantly associated with a complete response (P < 0.001). When cancer was divided into stages I/II and III/IV, patients with a low NLR had a significantly better therapeutic outcome than those with a high NLR (P < 0.05). Multivariate analysis showed that only the NLR was a significant prognostic factor for progression-free survival (PFS) and overall survival (OS). Patients with a high NLR had significantly shorter PFS and OS than those with a low NLR. CONCLUSION: Results showed that a low NLR before treatment could predict a good response to RT or CCRT at all stages of uterine cervical cancer. The NLR may be a promising parameter on which to base the choice of a therapeutic strategy to treat SCC of the uterine cervix.
Authors: Karim J Halazun; Mark A Hardy; Abbas A Rana; David C Woodland; Elijah J Luyten; Suhari Mahadev; Piotr Witkowski; Abbey B Siegel; Robert S Brown; Jean C Emond Journal: Ann Surg Date: 2009-07 Impact factor: 12.969
Authors: Dan Wang; Ming Wu; Feng-zhi Feng; Hui-fang Huang; Jia-xin Yang; Keng Shen; Yang Xiang Journal: Chin Med J (Engl) Date: 2013 Impact factor: 2.628
Authors: Rūta Grigiene; Konstantinas P Valuckas; Eduardas Aleknavicius; Juozas Kurtinaitis; Simona R Letautiene Journal: BMC Cancer Date: 2007-12-22 Impact factor: 4.430
Authors: Caroline A Young; Louise J Murray; Ebru Karakaya; Helene H Thygesen; Mehmet Sen; Robin J D Prestwich Journal: Clin Med Insights Oncol Date: 2014-06-29
Authors: David S Lakomy; Juliana Wu; Dorothy Lombe; Emmanouil Papasavvas; Susan Citonje Msadabwe; Yimin Geng; Luis J Montaner; Elizabeth Chiao; Lilie L Lin Journal: Cancer Med Date: 2021-06-12 Impact factor: 4.452